Featured Research

from universities, journals, and other organizations

Toxicity profile informs decision on preferred conditioning regimen in autologous transplant for neuroblastoma

Date:
April 24, 2013
Source:
Dana-Farber Cancer Institute
Summary:
The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study.

The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study to be presented at the 26th annual meeting of the American Society of Pediatric Hematology Oncology in Miami April 24-27. The U.S. regimen was associated with more acute toxicity to the kidneys and liver.

This and other research informed the recent decision of the Children's Oncology Group (COG) to switch to the busulfan-based regimen used for years in Europe and Egypt, said senior author Leslie E. Lehmann, MD, clinical director of pediatric stem cell transplantation at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) in Boston.

Both approaches to high-risk neuroblastoma employ high doses of chemotherapy to eradicate cancer cells followed by infusion of the patient's previously collected stem cells to allow the patient to recover more quickly and safely. Since 2007, physicians at DF/CHCC and others in the Children's Oncology Group had been using a combination of high-dose carboplatin, etoposide, and melphalan to prepare patients for transplant, said Lehmann. European centers have preferred busulfan and melphalan over the platinum-based regimen.

"We have had a long-standing collaboration with Children's Cancer Hospital Egypt in Cairo, which is under the leadership of senior author Dr. Alaa Elhaddad," Lehmann said. "We decided to compare the toxicities in patients who received care that was very similar except for the drugs used in the preparative regimen.

"We found there was no difference in survival, but our regimen was associated with more liver and kidney toxicity and more bloodstream infections," she noted. "This was very useful information as COG contemplated switching to the European approach."

In addition to the idea of using toxicity data to choose between approaches of similar efficacy, Lehmann noted, "This study demonstrates you can have true collaboration between transplant centers located in very different parts of the world."

First author of the study is Yasser Elborai, MD, of the Children's Cancer Hospital Egypt.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. The original article was written by Richard Saltus. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Toxicity profile informs decision on preferred conditioning regimen in autologous transplant for neuroblastoma." ScienceDaily. ScienceDaily, 24 April 2013. <www.sciencedaily.com/releases/2013/04/130424140518.htm>.
Dana-Farber Cancer Institute. (2013, April 24). Toxicity profile informs decision on preferred conditioning regimen in autologous transplant for neuroblastoma. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2013/04/130424140518.htm
Dana-Farber Cancer Institute. "Toxicity profile informs decision on preferred conditioning regimen in autologous transplant for neuroblastoma." ScienceDaily. www.sciencedaily.com/releases/2013/04/130424140518.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins